La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

BrainCool Salute del bilancio

Salute finanziaria criteri di controllo 4/6

BrainCool ha un patrimonio netto totale di SEK165.4M e un debito totale di SEK0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente SEK182.4M e SEK17.0M.

Informazioni chiave

Rapporto debito/patrimonio netto

SEK 0

Debito

Indice di copertura degli interessi	n/a
Contanti	SEK 58.61m
Patrimonio netto	SEK 165.40m
Totale passività	SEK 17.01m
Totale attività	SEK 182.41m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Is BrainCool (NGM:BRAIN) In A Good Position To Invest In Growth?

Mar 24

Here's Why BrainCool (NGM:BRAIN) Can Afford Some Debt

Nov 17

We Think BrainCool (NGM:BRAIN) Has A Fair Chunk Of Debt

Jul 23

Is BrainCool (NGM:BRAIN) A Risky Investment?

Mar 07

How Much Did BrainCool's(NGM:BRAIN) Shareholders Earn From Share Price Movements Over The Last Five Years?

Jan 14

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( SEK98.4M ) di BRAIN superano le sue passività a breve termine ( SEK17.0M ).

Passività a lungo termine: BRAIN non ha passività a lungo termine.

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: BRAIN è esente da debiti.

Riduzione del debito: BRAIN non ha debiti rispetto a 5 anni fa, quando il suo rapporto debito/patrimonio netto era 13.9%.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: BRAIN ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: BRAIN ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 9.5 % ogni anno

BrainCool Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Is BrainCool (NGM:BRAIN) In A Good Position To Invest In Growth?

Here's Why BrainCool (NGM:BRAIN) Can Afford Some Debt

We Think BrainCool (NGM:BRAIN) Has A Fair Chunk Of Debt

Is BrainCool (NGM:BRAIN) A Risky Investment?

Recent updates

Second quarter 2024 earnings released

Braincool AB (Publ) Approves Board Appointments

BrainCool AB (publ) Announces Roger Henriksson Declines Re-Election as Board Member

BrainCool AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 85.763172 million.

BrainCool AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 85.763172 million.

BrainCool AB (publ) to Report Fiscal Year 2024 Results on Feb 10, 2025

Full year 2023 earnings released

Braincool AB (Publ) Announces Karolinska Starts the Clinical Study PRINCESS 2 with BrainCool's Product RhinoChill® System

New major risk - Share price stability

BrainCool AB (publ) and University of Freiburg Announces Start of Pivotal Clinical Trial (Cottis 2) for Combined Target Temperature Management and Thrombectomy After Ischemic Stroke

CEO & Director recently sold kr254k worth of stock

Third quarter 2023 earnings released

Braincool AB (Publ) Announces New Clinical Study Evaluating Early Hypothermia Treatment After Cardiac Arrest with the Braincool System and Rhinochill System

CEO & Director recently bought kr53k worth of stock

American Medical Association Approves New Current Procedural Terminology Code for Cryotherapy Using BrainCool's Cooral System

BrainCool AB (publ) Announces New CPT Code from AMA for Cooral® System supports Pathway to Reimbursement in the U.S

CEO & Director recently bought kr62k worth of stock

Second quarter 2023 earnings released

New major risk - Share price stability

Braincool AB (Publ) Introduces Minichill in Japan

Braincool AB (Publ) Announces New Patent Application for Rhinochill Technology Paves the Way for New Possibilities

BrainCool AB (publ) Receives Patent Approval for "Shivering" in the EU for the Product BrainCool System

Braincool AB (Publ) Announces International Clinical Study with Rhinochill®System of Patients with Sudden Cardiac Arrest Obtain Ethical Approval

First quarter 2023 earnings released

BrainCool AB (publ) to Report Q3, 2023 Results on Nov 30, 2023

BraincCool Launches New Commercialization Strategy for Its Breakthrough Product Cooral ®System Aiming for Reimbursement in the U.S

Is BrainCool (NGM:BRAIN) In A Good Position To Invest In Growth?

BrainCool AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

Third quarter 2022 earnings released: kr0.17 loss per share (vs kr0.12 loss in 3Q 2021)

Here's Why BrainCool (NGM:BRAIN) Can Afford Some Debt

No independent directors

BrainCool AB (publ) to Report Q3, 2022 Results on Nov 30, 2022

BrainCool AB (publ) Announces FDA approval of Cooral

Second quarter 2022 earnings released: kr0.18 loss per share (vs kr0.13 loss in 2Q 2021)

We Think BrainCool (NGM:BRAIN) Has A Fair Chunk Of Debt

First quarter 2022 earnings released: kr0.14 loss per share (vs kr0.12 loss in 1Q 2021)

BrainCool AB (publ) to Report Q1, 2022 Results on May 31, 2022

No independent directors

CEO & Director recently bought kr73k worth of stock

CEO & Director recently bought kr195k worth of stock

CEO & Director recently bought kr195k worth of stock

CEO & Director recently bought kr195k worth of stock

Is BrainCool (NGM:BRAIN) A Risky Investment?

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2021 earnings released: kr0.13 loss per share (vs kr0.15 loss in 2Q 2020)

CEO & Director recently bought kr238k worth of stock

BrainCool AB (publ), Annual General Meeting, Apr 15, 2021

Full year 2020 earnings released: kr0.68 loss per share (vs kr1.43 loss in FY 2019)

BrainCool AB (publ) Receives FDA "Breakthrough Device" Designation for Cooral® System for Prevention of Oral Mucositis

New 90-day high: kr9.17

How Much Did BrainCool's(NGM:BRAIN) Shareholders Earn From Share Price Movements Over The Last Five Years?

Third quarter 2020 earnings released: kr0.12 loss per share

New 90-day low: kr7.00

Braincool AB Announces Statistically Significant Late-Breaking Clinical Data At SMO Virtual Congress 2020

New 90-day high - kr11.24

BrainCool AB (publ) to Report Q2, 2020 Results on Aug 28, 2020

New 90-day high - kr7.15

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane